Cerca
Menu
Foto del docente

Muller Fabbri

Professore a contratto

Dipartimento di Scienze Mediche e Chirurgiche

Pubblicazioni

  1. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65(16):7065-7070, 2005.
  2. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102(39):13944-13949, 2005.
  3. Fabbri M, Iliopoulos D, Trapasso F, Aqeilan RI, Cimmino A, Zanesi N, Yendamuri S, Han SY, Amadori D, Huebner K, Croce CM. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A 102(43):15611-15616, 2005.
  4. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353(17):1793-1801, 2005.
  5. Calin GA, Garzon R, Cimmino A, Fabbri M, Croce CM. MicroRNAs and leukemias: how strong is the connection? Leukemia Res 30(6):653-655, 2006.
  6. Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM, Huebner K. Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25(20):2860-2872, 2006.
  7. Qin HR, Iliopoulos D, Semba S, Fabbri M, Druck T, Volinia S, Croce CM, Morrison CD, Klein RD, Huebner K. A role for the WWOX gene in prostate cancer. Cancer Res 66(13):6477-6481, 2006.
  8. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med 12(12):580-587, 2006.
  9. Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K. Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 13(1):268-274, 2007.
  10. Donati V, Fontanini G, Dell'Omodarme M, Prati MC, Nuti S, Lucchi M, Mussi A, Fabbri M, Basolo F, Croce CM, Aqeilan RI. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 13(3):884-891, 2007.
  11. Sever NI, Younan S, Wojcik S, Spizzo R, Fabbri M, Calin GA. Use of miRNA expression profiling to identify novel biomarkers. Personalized Medicine 4(2):147-155, 2007.
  12. Fabbri M, Ivan M, Negrini M, Calin GA. Regulatory mechanisms of microRNAs involvement in cancer: the strange case of dr. Jekyll and mr. Hyde. Expert Opin Biol Ther 7(7):1009-1019, 2007.
  13. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, Shimizu M, Tili E, Rossi S, Taccioli C, Pichiorri F, Liu X, Zupo S, Herlea V, Gramantieri L, Lanza G, Alder H, Rassenti L, Volinia S, Schmittgen TD, Kipps TJ, Negrini M, Croce CM. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12(3):215-229, 2007.
  14. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104(40):15805-15810, 2007.
  15. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 179(8):5082-5089, 2007.
  16. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin GA. MicroRNAs and Noncoding RNAs in Hematological Malignancies: Molecular, Clinical, and Therapeutic Implications. Leukemia 22(6):1095-1105, 2008.
  17. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 14(1):1-6, 2008.
  18. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111(6):3183-3189, 2008.
  19. Calin G.A., Cimmino A., Fabbri M*, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu C-G, Kipps TJ, Negrini M, Croce CM. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 105(13):5166-5171, 2008. *First Author equal contribution.
  20. Fabbri M, Garzon R. Implications of microRNAs in normal hematopoiesis and human leukemia. Clin Leukemia 2(2):96-101, 2008.
  21. Fabbri M, MicroRNAs and cancer epigenetics. Curr Opin Investig Drugs 9(6):583-590, 2008.
  22. Cimmino A, Capasso R, Fabbri M, Sambri I, Masella L, Raimo M, De Bonis ML, D'Angelo S, Zappia V, Galletti P, Ingrosso D. Protein isoaspartate methyltransferase prevents apoptosis induced by oxidative stress in endothelial cells: role of Bcl-Xl deamidation and methylation. PLoS One 3(9):e3258, 2008.
  23. Fabbri M, Croce CM, Calin GA. MicroRNAs in the Ontogeny of Leukemias and Lymphomas. Leuk Lymphoma 50(2):160-170, 2009.
  24. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G. MicroRNA -29b induces global DNA hypomethylation and tumor suppressor gene re-expression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113(25):6411-6418, 2009.
  25. Fabbri M, Valeri N, Calin GA. MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis 30(6):912-917, 2009.
  26. Fanini F., Vannini I., Fabbri M. MicroRNAs: tiny players with a big role in the pathogenesis of leukemias and lymphomas. Hematol Rev 1:e8, 2009.
  27. Valeri N, Croce CM, Fabbri M. Pathogenetic and clinical relevance of MicroRNAs in colorectal cancer. Cancer Genomics Proteomics 6(4):195-204, 2009.
  28. Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M. Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 20(9-10):573-580, 2009.
  29. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce CM. MicroRNA 29b functions in acute myeloid leukemia. Blood 114(26):5331-5341, 2009.
  30. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17(2):246-254, 2010.
  31. Valeri N, Gasparini P, Fabbri M*, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, Costinean S, Sandhu SK, Nuovo GJ, Alder H, Gafa R, Calore F, Ferracin M, Lanza G, Volinia S, Negrini M, McIlhatton MA, Amadori D, Fishel R, Croce CM. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 107(15):6982-6987, 2010. *First Author equal contribution.
  32. Fabbri M, Calin GA. Beyond Genomics: Interpreting the 93% of the human genome that does not code for proteins. Curr Opin Drug Discov Devel 13(3):350-358, 2010.
  33. Gatto S, Della Ragione FD, Cimmino A, Strazzullo M, Fabbri M, Mutarelli M. Ferraro L, Weisz A, D’Esposito M, Matarazzo MR. Epigenetic alteration of microRNAs in DNMT3B-mutated patients of ICF syndrome. Epigenetics 5(5):427-443, 2010.
  34. Fabbri M. miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn 10(4):435-444, 2010.
  35. Fabbri M, Spizzo R, Calin GA. High-throughput profiling in the hematopoietic system. Methods Mol Biol 667:79-91, 2010.
  36. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genetics 70:87-99, 2010.
  37. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20(5):589-599, 2010.
  38. Cohn DE, Fabbri M, Valeri N, Alder H, Ivanov I, Liu CG, Croce CM, Resnick KE. Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol 202(6):656.e1-8, 2010.
  39. Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M, Sumani K, Alder H, Amadori D, Patel T, Nuovo G, Fishel R, Croce CM. miR-21 induces resistance to 5-Fluorouracil by down-regulating hMSH2. Proc Natl Acad Sci U S A 107(49):21098-21103, 2010.
  40. Nana-Sinkam P, Fabbri M, Croce CM. MicroRNA in cancer: personalizing diagnosis and therapy. Ann N Y Acad Sci 1210:25-33, 2010.
  41. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6):945-52, 2010.
  42. Fanini F, Vannini I, Fabbri M. MicroRNAs and drug modulation in cancer: an intertwined new story. Front Biol 6(5):351-356, 2011.
  43. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso M, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik S, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri R, Rassenti L, Negrini M, Nakamura T, Amadori D, Kay N, Rai K, Keating M, Kipps T, Calin G, Croce CM. Association of a microRNA/TP53 feedback circuitry with the pathogenesis and prognostic factors of B-Chronic Lymphocytic Leukemia. JAMA 305(1):59-67, 2011.

    This paper received the following special Editorial:

    Allendorf DJ, and Davis RS. Unraveling the molecular pathogenesis of Chronic Lymphocytic Leukemia: dissecting a microRNA regulatory network. JAMA 305(1):98, 2011.

  44. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer, and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 17(9):2725-2733, 2011.
  45. Fabbri M, Croce CM. Role of microRNAs in lymphoid biology and disease. Curr Opin Hematol 18(4):266-272, 2011.
  46. Paone A, Galli R, Fabbri M. MicroRNAs as new characters in the plot between epigenetics and prostate cancer. Front Genet 2:62, 2011.
  47. Fanini F, Vannini I, Amadori D, Fabbri M. Clinical Implications of MicroRNAs in Lung Cancer. Sem Oncol 38(6):776-80, 2011.
  48. Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafà R, Xiao L, Zhang X, Vannini I, Fanini F, Fabbri M, Lanza G, Reis RM, Zweidler-McKay PA, Calin GA. Strand-Specific miR-28-5p and miR-28-3p Have Distinct Effects in Colorectal Cancer Cells. Gastroenterology 142(4):886-96, 2012.
  49. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H, Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 109(31):E2110-6, 2012.
  50. Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M*, Sasako M, Maehara Y, Mimori K, Mori M. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br. J. Cancer 107(8):1345-53, 2012.

    * First Author Equal Contribution

  51. Fabbri M. TLRs as miRNA receptors. Cancer Res. 72(24):6333-7, 2012.
  52. McCleary-Wheeler AL, Lomberk GA, Weiss FU, Schneider G, Fabbri M, Poshusta TL, Dusetti NJ, Baumgart S, Iovanna JL, Ellenrieder V, Urrutia R, Fernandez-Zapico ME. Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett. 328(2):212-21, 2013.
  53. Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CM. Heat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas. Blood 121(2):351-9, 2013.
  54. Fabbri M, Calore F, Paone A, Galli R, Calin GA. Epigenetic Regulation of miRNAs in Cancer. [http://www.ncbi.nlm.nih.gov/pubmed/22956499] Adv Exp Med Biol 754:137-48, 2013.
  55. Fabbri M, Paone A, Calore F, Galli R, Croce CM. A new role for microRNAs, as ligands of Toll-like receptors. [http://www.ncbi.nlm.nih.gov/pubmed/23296026] RNA Biol. 10(2):169-74, 2013.
  56. Kang HW, Crawford M, Fabbri M, Nuovo G, Garofalo M, Nana-Sinkam SP, Friedman A. A Mathematical Model for MicroRNA in Lung Cancer. [http://www.ncbi.nlm.nih.gov/pubmed/23365639] PLoS One. 8(1):e53663, 2013.
  57. Vannini I, Fanini F, Fabbri M. MicroRNAs as lung cancer biomarkers and key players in lung carcinogenesis. Clin Biochem 46(10-11):918-25, 2013.
  58. Galli R, Paone A, Fabbri M, Zanesi N, Calore F, Cascione L, Acunzo M, Stoppacciaro A, Tubaro A, Lovat F, Gasparini P, Fadda P, Alder H, Volinia S, Filippini A, Ziparo E, Riccioli A, Croce CM. Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression. Proc Natl Acad Sci U S A 110(24):9812-7,2013.
  59. Fabbri M. MicroRNAs and cancer: towards a personalized medicine. Curr Mol Med 13(5):751-6, 2013.
  60. Liu SV, Fabbri M, Gitlitz BJ, Laird-Offringa I. Epigenetic therapy in lung cancer. Front Oncol 3:135, 2013.
  61. Aalaei-Andabili SH, Fabbri M, Rezaei N. Reciprocal effects of Toll-like receptors and miRNAs on biological processes in human health and disease: a systematic review. Immunotherapy 5(10):1127-42, 2013.
  62. Ling H, Fabbri M*, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12(11):847-65, 2013.

    * First Author Equal Contribution

  63. de Rosa F, Fanini F, Guidoboni M, Vannini I, Amadori D, Ridolfi R, Ridolfi L, Fabbri M. MicroRNAs and dendritic cell-based vaccination in melanoma patients. [http://www.ncbi.nlm.nih.gov/pubmed/24638153] Melanoma Res 24(3):181-9, 2014.
  64. Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, Paone A, Cascione L, Sumani KM, Veronese A, Fabbri M, Carasi S, Alder H, Lanza G, Gafa' R, Moyer MP, Ridgway RA, Cordero J, Nuovo GJ, Frankel WL, Rugge M, Fassan M, Groden J, Vogt PK, Karin M, Sansom OJ, Croce CM. MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer. [http://www.ncbi.nlm.nih.gov/pubmed/24735923] Cancer Cell 25(4):469-83, 2014.
  65. Challagundla KB, Fanini F, Vannini I, Wise P, Murtadha M, Malinconico L, Cimmino A, Fabbri M. microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 14(5):565-74, 2014.
  66. Tudor S, Giza DE, Lin HY, Fabris L, Yoshiaki K, D'Abundo L, Toale KM, Shimizu M, Ferracin M, Challagundla KB, Angelica Cortez M, Fuentes-Mattei E, Tulbure D, Gonzalez C, Henderson J, Row M, Rice TW, Ivan C, Negrini M, Fabbri M, Morris JS, Yeung SC, Vasilescu C, Calin GA. Cellular and Kaposi's sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. Cell Death Dis Dec 4;5:e1559, 2014.
  67. Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock MD, Braicu C, Pileczki V, Vincent K, Pichler M, Stiegelbauer V, Hoefler G, Almeida MI, Hsiao A, Zhang X, Primrose JN, Packham GK, Liu K, Bojja K, Gafà R, Xiao L, Rossi S, Song JH, Vannini I, Fanini F, Kopetz S, Zweidler-McKay P, Wang X, Ionescu C, Irimie A, Fabbri M, Lanza G, Hamilton SR, Berindan-Neagoe I, Medico E, Mirnezami AH, Calin GA, Nicoloso MS. The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut 65(6):977-89, 2015.
  68. Fei F, Joo EJ, Tarighat SS, Schiffer I, Paz H, Fabbri M, Abdel-Azim H, Groffen J, Heisterkamp N. B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3. Oncotarget 6(13):11378-94, 2015.
  69. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, Kennedy R, Ivan C, Zhang X, Vannini I, Fanini F, Amadori D, Calin GA, Hadjidaniel M, Shimada H, Jong A, Seeger RC, Asgharzadeh S, Goldkorn A, Fabbri M. Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. J Natl Cancer Inst 107(7), 2015. doi: 10.1093/jnci/djv135.
  70. Neviani P, Fabbri M. Exosomic microRNAs in the Tumor Microenvironment. Front Med (Lausanne) 2:47, 2015.
  71. Olivieri M, Ferro M, Terreri S, Durso M, Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D, Vannini I, Marinelli L, Novellino E, Zhang W, Incoronato M, Ilardi G, Staibano S, Marra L, Franco R, Perdonà S, Terracciano D, Czerniak B, Liguori GL, Colonna V, Fabbri M, Febbraio F, Calin GA, Cimmino A. Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget. 2016, 7 (15):20636-54.
  72. Frediani JN, Fabbri M. Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer May 26;15(1):42, 2016.
  73. Giza DE, Fuentes-Mattei E, Bullock MD, Tudor S, Goblirsch MJ, Fabbri M, Lupu F, Yeung SJ, Vasilescu C, Calin GA. Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications. Cell Death Differ 23(12):1906-18, 2016.
  74. Murtadha M, Fabbri M. Exosomic microRNAs as emerging key regulators of intercellular communication in the tumor microenvironment and beyond. microRNA Diagn Ther; 2:1-12, 2016.
  75. Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis R, D'Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo P, Ruvolo VR, Pecot CV, Amadori D, Aruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski RZ, Plunkett W, Lichtenberg T, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Hagop K, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M*, Calin GA. Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res 2016 Nov 30. Pii: clincanres.1025.

    *Senior Author co-corresponding Author

  76. Fanini F., Fabbri M. Cancer-derived exosomic microRNAs shape the Immune System within the Tumor Microenvironment: State of the Art. Semin Cell and Develop Biol, (16):30456-6, 2016.

  77. Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon R. Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. J Immunol, 198(6):2500-2512, 2017.
  78. Jong AY, Wu CH, Li J, Sun J, Fabbri M, Wayne AS, Seeger RC. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles, 6(1):1294368, 2017.
  79. Guire V, Fabbri M, Tsongalis GJ. Not all good things come in big packages. Clin Chem Lab Med, 55(5):605-7, 2017.
  80. Sempere LF, Keto J, Fabbri M. Exosomal MicroRNAs in Breast Cancer towards Diagnostic and Therapeutic Applications. Cancers (Basel), 24(9):pii: E71, 2017.
  81. Guo J, Jayaprakash P, Dan J, Wise P, Jang GB, Liang C, Chen M, Woodley DT, Fabbri M, Li W. PRAS40 Connects Microenvironmental Stress Signaling to Exosome-Mediated Secretion. Mol Cell Biol, Jul 3. pii: MCB.00171-17, 2017.
  82. Nakata R, Shimada H, Fernandez GE, Fanter R, Fabbri M, Malvar J, Zimmermann P, DeClerck YA. Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. J Extracell Vesicles Jun 25;6(1):1332941, 2017.
  83. Barbato S, Solaini G, Fabbri M. MicroRNAs in Oncogenesis and Tumor Suppression. Int Rev Cell Mol Biol 333:229-268, 2017.
  84. Samuel P, Fabbri M, Carter DRF. Mechanisms of drug resistance in cancer: The role of extracellular vesicles. Proteomics Sep 23. Doi: 10.1002/pmic.201600375. [Epub ahead of print]. 2017.
  85. Vannini I, Wise PM, Challagundla KB, Plousiou M, Raffini M, Bandini E, Fanini F, Paliaga G, Crawford M, Ferracin M, Ivan C, Fabris L, Davuluri RV, Guo Z, Cortez MA, Zhang X, Chen L, Zhang S, Fernandez-Cymering C, Han L, Carloni S, Salvi S, Ling H, Murtadha M, Neviani P, Gitlitz BJ, Laird-Offringa IA, Nana-Sinkam P, Negrini M, Liang H, Amadori D, Cimmino A, Calin GA, Fabbri M. Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. Nat Commun in press, 2017.

Ultimi avvisi

Al momento non sono presenti avvisi.

RSS